Publications by authors named "Machiko Nakatogawa"
Article Synopsis
- - This study assessed how effective and safe linaclotide is for treating chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) in patients who didn't respond to magnesium oxide.
- - Conducted over 12 weeks, 61 participants showed significant improvements in quality of life and bowel movement frequency, with noticeable changes in various symptoms measured on standard scales.
- - The findings suggest that linaclotide could be a viable treatment for elderly patients with CC who haven't had success with traditional treatments, although some experienced diarrhea which was manageable.
Background/aims: The precise incidence of symptomatic uncomplicated diverticular disease (SUDD) and its effects on the quality of life (QOL) remain unclear, particularly in Asian patients with right-sided SUDD. We assess the prevalence of SUDD and its impact on QOL in a real-world population.
Methods: Five institutional cohorts of patients who received outpatient treatment for unexplained abdominal symptoms from January 15, 2020 to March 31, 2022, were included.
Exploratory, multicenter, open-label study to evaluate the effects of linaclotide in patients with chronic constipation with an insufficient response to magnesium oxide: A study protocol.
Contemp Clin Trials Commun
December 2022
Background: Chronic constipation leads to poor quality of life, and treatment remains unsatisfactory for patients. In Japan, magnesium oxide has been commonly used as the first choice of treatment for constipation; however, there are some cases of low satisfaction with magnesium oxide treatment. Linaclotide has recently been used to treat chronic constipation.
View Article and Find Full Text PDFBackground: Approximately 60% of patients with chronic constipation (CC) have a significantly higher rate of loss of defecation desire (LODD). Bile acids are expected to have a restorative effect on defecation desire (DD) because they lower the rectal sensory threshold, which is an objective index of DD. Elobixibat (EXB) specifically inhibits the ileal bile acid transporter/apical sodium-dependent bile acid transporter, which is a transporter involved in the reabsorption of bile acids in the terminal ileum.
View Article and Find Full Text PDFIntroduction: Chronic constipation (CC) is a functional disorder that negatively impacts the quality of life of patients. This is a protocol for a multicentre, 12-week, randomised, double-blind, placebo-controlled study to test the efficacy and safety of elobixibat (EXB) versus placebo in patients with CC.
Methods And Analysis: This will be a multicentre, double-blind, placebo-control, randomised controlled trial.